Targeted therapies and clinical trials in ovarian cancer.

Abstract excerpt

Recent advances in molecular profiling have shown that cancers arising from the ovary are phenotypically and genetically heterogeneous. Within histologies, many mutations in druggable targets are uncommon in frequency but mutations leading to activation of specific signal transduction pathways are common. These results support the notion that different targeted agents should be prioritized for testing between and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clinical Trials as Topic
• Share to Molecular Targeted Therapy
• Share to Mutation